Replicel presentation january 12th

They are having another presentation, I doubt that much new info will be revealed but David Hall has been dropping details like crazy.http://www.itbusinessnet.com/article...ncisco-3688408

That means today, looking forward to it.

Any news about the meeting? I didn't find anything on their website

Quote:

---

Originally Posted by efedrez

Any news about the meeting? I didn't find anything on their website

---

The presentations go on until January 14th, so today will be the last day.

There's also this interview that took place about tendonosis:

http://espn.go.com/espnradio/newyork/play?id=12144813

Biotech Showcase presentation has been posted.

Note the RCH-01 trial is scheduled for H1 2015. So it can start anytime between now and mid-year.

http://www.replicel.com/wp-content/u...2015-FINAL.pdf

Quote:

---

Originally Posted by macbeth81

Biotech Showcase presentation has been posted.

Note the RCH-01 trial is scheduled for H1 2015. So it can start anytime between now and mid-year.

http://www.replicel.com/wp-content/u...2015-FINAL.pdf

---

Thanks! I wonder if this time they will really start the trial, last year it was the same for Q1, then Q2 then second half of 2014, and now H1 2015.

I believe there were dealing with a few bureaucratic issues that were resolved list year.

Also we should pay attention to Shiseido trial also starting this year

Could they AT LEAST get the ball rolling with the japanese trials from Shiseido??

I really think that now since their partnership is more settled they won't be so slow with trials. Im sure there will be some delays though, I understand its not like going to the dmv and getting a new licence.

I think they will definitely start in first half of this year, however this Phase 2 is make it or break it for Replicel.

This is an excerpt from the pdf:

Quote:

---

1. 160 participants
2. 396 RCH-01 treatment group sites (vs. 16 in P1), with 244 placebo sites
3. Designed to measure dosing and treatment frequency
4. Primary commercial endpoint –efficacy at 52 weeks after final injection
   efficacy measured as total density, hair thickness, cumulative hair and treatment response rate
   
5. Secondary endpoints –52 weeks
   local tolerance, systemic safety

---

Notice the bolded part: after 52 weeks (1 year) we will get the results for the Phase 2 data. That is when we will know how good RCH-01 really is. This is good. At least we won't be kept in the dark.
So expect results in H2 of 2016.

As for Shiseido I don't expect they will be forthcoming with news for the international scene. I think they will conduct their trials away from the public eye.